NumFin

Eris Lifesciences Limited

符号: ERIS.NS

NSE

843.7

INR

今天的市场价格

  • 29.8535

    市盈率

  • 2.0937

    PEG比率

  • 114.78B

    MRK市值

  • 0.00%

    DIV收益率

Eris Lifesciences Limited (ERIS-NS) 财务报表

Download
年度季度
线性对数
在图表中，您可以看到 的动态默认数字 Eris Lifesciences Limited (ERIS.NS). 的默认数据。公司收入显示 8937.308 M 的平均值，即 0.127 % 增长率。整个期间的平均毛利润为 7297.222 M，即 0.122 %. 平均毛利率为 0.820 %. 公司去年的净收入增长率为 -0.059 %，等于 0.173 % % 整个公司历史的平均增长率.,

年度季度
10Y20Y30Y40Y

资产负债表

深入分析 Eris Lifesciences Limited 的财务轨迹，我们可以看到其平均资产增长率。有趣的是，这一增长率为 ，反映了公司的高点和低点。与季度相比，这一数字调整为0. 回顾过去一年，总资产变化为 0.238. 在流动资产领域，ERIS.NS 的报告货币为7647.22. 这些资产中的很大一部分，即 892.43 是现金和短期投资。与去年的数据相比，该部分的变化率为-0.496%. 公司的长期投资虽然不是其重点，但以报告货币计算的68.77（如果有的话）为68.77。这表明与上一报告期相比，-98.366% 的差异反映了公司的战略转变. 公司的债务概况显示，以报告货币计算的长期债务总额为 6834.21. 这一数字表明，11.455% 的年同比变化. 股东权益总额所体现的股东价值是以报告货币计算的 21959.88. 这方面的年同比变化率为 0.151%. 深入了解公司财务信息后，会发现更多细节。应收账款净额的估值为2966.95，存货估值为 1314.35，商誉估值为 3318.49（如有. 无形资产总额（如果有）按 18805.96 估值. 应付账款和短期债务分别为 1247.69 和 1932.9. 债务总额为8767.11，债务净额为 8206.89. 其他流动负债为 217.22，加上总负债 14466.51. 最后，如果存在推荐股票，则其估值为 21930.12.

common:word.in-mln

USD
Growth
TTM20222021202020192018201720162015201420132012

balance-sheet.row.cash-and-short-term-investments

5613.44892.41772.4522.7
1419.9
3224.4
1044
2609
741.9
749.6
742.5
514

balance-sheet.row.short-term-investments

6124.75332.21264.5154
747.8
3149.4
937.9
2584.8
653.2
692.4
669.6
465

balance-sheet.row.net-receivables

6515.972966.92260.92280.6
2076.4
1760.4
1287.5
604
373.4
0
0
0

balance-sheet.row.inventory

2705.241314.31179.1944.7
694.8
826.5
654.5
558.2
476.2
576
448.1
432

balance-sheet.row.other-current-assets

5222.752473.51060.8922.5
2681.5
6.5
1.1
73.5
1.4
309.1
364.2
317.6

balance-sheet.row.total-current-assets

20057.47647.26273.34670.5
4796.2
5817.8
2987.1
3844.8
1592.9
1634.8
1554.8
1263.5

balance-sheet.row.property-plant-equipment-net

7998.423773.81918.6778.8
872.4
560.7
526.1
553.9
706.7
675
710.5
235.2

balance-sheet.row.goodwill

6636.983318.5934.7934.7
934.7
935.9
1869.5
792.6
0
35.5
32.2
32.8

balance-sheet.row.intangible-assets

37042.031880665966840.8
6984.7
6136.1
6250.1
363.3
7
6.9
6.6
0.8

balance-sheet.row.goodwill-and-intangible-assets

43679.0122124.57530.77775.5
7919.4
7071.9
8119.6
1156
7
42.4
38.7
33.7

balance-sheet.row.long-term-investments

16.4368.84208.42859.2
32
409.1
1778.2
-2483.9
890.3
280.4
-499.6
-464.9

balance-sheet.row.tax-assets

5690.482739.42431.32006.3
1709.1
1447.9
1005.7
95.2
186.9
33.1
2.1
2.6

balance-sheet.row.other-non-current-assets

-2016.58319.6359257.6
193.9
229.1
184.2
3244.1
802
907.2
899.4
648

balance-sheet.row.total-non-current-assets

55367.7629026.116448.113677.3
10726.9
9718.8
11613.8
2565.2
2592.9
1938.1
1151.2
454.5

balance-sheet.row.other-assets

0000
0
0
0
0
0
0
0
0

balance-sheet.row.total-assets

75425.1636673.322721.418347.8
15523
15536.6
14600.9
6410
4185.8
3572.8
2706
1718

balance-sheet.row.account-payables

2752.941247.71177.71026.2
1000.5
841.3
0
385.2
0
367.1
373.8
220.2

balance-sheet.row.short-term-debt

3903.211932.940.123.3
60
1761.3
1026
72.7
5
28.6
79.4
62.2

balance-sheet.row.tax-payables

176.96397077.5
70
18.1
25.6
0
170.5
0
0
0

balance-sheet.row.long-term-debt-total

13158.946834.2803.944.5
61.4
2.9
2741.9
4.9
0
5
0
5.6

Deferred Revenue Non Current

623.4987.456.961.1
85.5
66.6
209.7
10.8
0
5.6
3
0.8

balance-sheet.row.deferred-tax-liabilities-non-current

5109.42---
-
-
-
-
-
-
-
-

balance-sheet.row.other-current-liab

438.6217.2152.4132.5
162.1
181.4
1228.6
58.6
684.5
40.2
41.3
24.4

balance-sheet.row.total-non-current-liabilities

19538.9510034.21642.9914.3
912.8
793
3486.5
252.5
255.8
218.2
180.9
174.2

balance-sheet.row.other-liabilities

0000
0
0
0
0
0
0
0
0

balance-sheet.row.capital-lease-obligations

903466.939467.7
121.4
0
0
0
0
0
0
0

balance-sheet.row.total-liab

28942.6614466.53639.42583.6
2559.7
3848.3
5741.1
1010.7
945.3
877
897.4
609.7

balance-sheet.row.preferred-stock

21930.1221930.119062.415722.7
13590.9
12056.2
0
0
0
0
0
0

balance-sheet.row.common-stock

272.01136135.9135.8
135.8
137.5
137.5
137.5
1.4
1.4
1.4
1.4

balance-sheet.row.retained-earnings

21559.321559.318736.515503.1
12797.3
11335.2
8468.6
5254.7
3200
2648.3
1756.7
1052.5

balance-sheet.row.accumulated-other-comprehensive-income-loss

70084.9829.820.741.5
-711.3
-544
-389.9
-620
0
-315.4
-163.3
-118

balance-sheet.row.other-total-stockholders-equity

-21288.35-21695.3-18872.5-15638.9
-12849.2
-11479.7
396.9
627
7
322.4
170.3
125

balance-sheet.row.total-stockholders-equity

92558.0621959.919083.115764.2
12963.3
11505.2
8613.1
5399.2
3208.4
2656.7
1765
1060.8

balance-sheet.row.total-liabilities-and-stockholders-equity

121907.6636673.322721.418347.8
15523
15536.6
14600.9
6410
4185.8
3572.8
2706
1718

balance-sheet.row.minority-interest

406.94246.9-1.10
0
183.1
246.7
0
32
39.2
43.5
47.5

balance-sheet.row.total-equity

9296522206.81908215764.2
12963.3
11688.3
8859.7
-
-
-
-
-

balance-sheet.row.total-liabilities-and-total-equity

121907.66---
-
-
-
-
-
-
-
-

Total Investments

5883.66143.54208.42436.4
32
409.1
2716.1
101
1543.5
972.8
170
0.1

balance-sheet.row.total-debt

17062.158767.1844.167.8
121.4
1764.2
3768
77.6
5
33.6
79.4
67.8

balance-sheet.row.net-debt

17573.468206.9336.1-300.9
-550.7
1689.2
3661.9
53.4
-83.7
-23.6
6.5
18.9

现金流量表

在 Eris Lifesciences Limited 的财务状况中，自由现金流在过去一段时间内发生了显著变化，呈现出 -0.264 的转变。该公司最近通过发行 22.78 扩大了股本，与上一年相比出现了0.044 的差异. 公司的投资活动产生了现金使用净额，按报告货币计算达到-9821010000.000. 与上一年相比， 2.073 发生了变化. 在同一时期，公司记录了 1170.88, 243.72 和 -3500，这对于了解公司的投资和还款策略具有重要意义. 公司的融资活动导致使用的现金净额为0.000，同比差异为0.000. 此外，公司还将-999.11 用于向股东分红。与此同时，该公司还采取了其他财务措施，即 7879.36，这也对其在此期间的现金流产生了重大影响. 这些组成部分合在一起，全面反映了公司的财务状况和现金流管理的战略方针。

common:word.in-mln

USD
Growth
TTM20222021202020192018201720162015201420132012

cash-flows.row.net-income

3864.394046.444223945
3313.5
3173.6
3122.3
2637.7
1544.4
1094.2
983.3
831.4

cash-flows.row.depreciation-and-amortization

1638.341170.9647429.9
502.6
363.5
256.4
237.4
203.6
155.1
47.7
34.9

cash-flows.row.deferred-income-tax

0-809.7-976.6-670.9
-585.1
-980.2
0
0
0
0
0
0

cash-flows.row.stock-based-compensation

31.2131.213.611.2
16.6
16.5
0
0
0
0
0
0

cash-flows.row.change-in-working-capital

0-1755.4-29953.3
-527.1
-532.4
-221.5
-163.7
-82
-80.6
207.3
-160.5

cash-flows.row.account-receivables

0-1171.4-204.8159
-747.9
-175.5
0
0
0
0
0
0

cash-flows.row.inventory

047.4-234.4-249.9
131.8
-172.1
4.2
-37.3
99.8
-127.9
-16.1
-206.3

cash-flows.row.account-payables

0-105151.625.7
159.3
55.1
0
0
0
0
0
0

cash-flows.row.other-working-capital

0-526.5-11.3118.6
-70.3
-239.9
-225.7
-126.4
-181.9
47.3
223.4
45.8

cash-flows.row.other-non-cash-items

-3895.6233.9-24.4-14.7
-9.5
188.9
-810.8
-712.8
-351.2
-268.1
-341.9
-325.6

cash-flows.row.net-cash-provided-by-operating-activities

2605.29000
0
0
0
0
0
0
0
0

cash-flows.row.investments-in-property-plant-an-equipment

0-8414.2-1210.3-257.6
-1512.8
-380
-251
-497.5
-236.4
-130.8
-519.3
-78.4

cash-flows.row.acquisitions-net

0-6554.9-103-2.8
-213.7
-30.7
-5279.6
35
0
0
0
0

cash-flows.row.purchases-of-investments

0-300-2677.7-3733.9
-381
-447.7
-1074.7
-1394.8
-207.2
-792.9
-332.3
-328.4

cash-flows.row.sales-maturities-of-investments

05204.4795.9774.2
3260.8
797.3
694.6
7.7
0
0
21.9
36.6

cash-flows.row.other-investing-activites

0243.7-1-13.4
79.6
10.6
9.7
17
4.5
2.4
2.3
13.6

cash-flows.row.net-cash-used-for-investing-activites

0-9821-3196.1-3233.6
1232.9
-50.5
-5901
-1841.1
-439.1
-921.3
-827.4
-356.7

cash-flows.row.debt-repayment

0-3500-450-0.1
-1755.1
-2002.1
0
-65.1
-5
-5.3
-20.6
-24.1

cash-flows.row.common-stock-issued

022.867.50
2851.9
8.9
0
0
0
0
0
0

cash-flows.row.common-stock-repurchased

03477.2-4500
-1016.8
0
0
0
0
0
0
0

cash-flows.row.dividends-paid

0-999.1-816.2-746.8
-469.8
0
0
-169.1
-830.8
0
0
0

cash-flows.row.other-financing-activites

07879.41201.8-77.1
-2956.2
-217.3
0
-2.4
-1.2
9.8
-2.5
-7.1

cash-flows.row.net-cash-used-provided-by-financing-activities

06880.3-447-824
-3345.9
-2210.5
3632.1
-236.6
-837
4.6
-23
-31.2

cash-flows.row.effect-of-forex-changes-on-cash

074.900
0
0
5.2
0
0
0
0
0

cash-flows.row.net-change-in-cash

2605.2951.5139.6-303.9
598.1
-31.1
82.7
-65.3
38.7
-16.2
45.8
-7.7

cash-flows.row.cash-at-end-of-period

6306.92560.2508.7369.1
673.1
75
106.1
23.4
88.7
50
66.2
20.4

cash-flows.row.cash-at-beginning-of-period

3701.63508.7369.1673.1
75
106.1
23.4
88.7
50
66.2
20.4
28.1

cash-flows.row.operating-cash-flow

2605.292917.43782.63753.6
2711.1
2230
2346.3
1998.7
1314.8
900.6
896.2
380.1

cash-flows.row.capital-expenditure

0-8414.2-1210.3-257.6
-1512.8
-380
-251
-497.5
-236.4
-130.8
-519.3
-78.4

cash-flows.row.free-cash-flow

2605.29-5496.82572.33496
1198.3
1849.9
2095.4
1501.2
1078.4
769.7
376.9
301.7

利润表行

Eris Lifesciences Limited 的收入与上期相比变化了 0.112%。据报告, ERIS.NS 的毛利润为 13094.66。该公司的营业费用为 8898.08，与上年相比变化了 38.967%. 折旧和摊销费用为 1170.88，与上一会计期间相比变化了 0.810%. 营业费用报告为 8898.08，显示38.967% 的同比变化。 销售和营销费用为 0, 其中 0.000% 与上年相比发生了变化。 基于近期数据的EBITDA为 0，同比增长0.104%. 营业收入为 4216.63，与上年相比变化了-0.007%. 净利润的变化率为 -0.059%。去年的净收入为3821.58.

common:word.in-mln

USD
Growth
TTM20222021202020192018201720162015201420132012

income-statement-row.row.total-revenue

18406.2216618.213261.711926.4
10581.8
9672
8556
7249.6
5970.2
5455.6
5088.2
3930.6

income-statement-row.row.cost-of-revenue

3346.183523.52608.12418.7
1787.4
1551.4
1362.2
1068
1005.9
961.7
1003.6
750.3

income-statement-row.row.gross-profit

15060.0413094.710653.69507.8
8794.5
8120.6
7193.8
6181.5
4964.3
4493.8
4084.6
3180.3

income-statement-row.row.gross-profit-ratio

0000
0
0
0
0
0
0
0
0

income-statement-row.row.research-development

61---
-
-
-
-
-
-
-
-

income-statement-row.row.selling-general-administrative

1189.54---
-
-
-
-
-
-
-
-

income-statement-row.row.selling-and-marketing-expenses

63.85---
-
-
-
-
-
-
-
-

income-statement-row.row.other-expenses

96.71111.510.44.5
36.6
17.4
7.4
0.9
0.2
0.8
1798.9
0

income-statement-row.row.operating-expenses

10245.468898.164035620
5559.6
5011.1
4229
3726
3422.8
3434.1
3141.8
2314.2

income-statement-row.row.cost-and-expenses

13591.6412421.69011.18038.7
7346.9
6562.5
5591.2
4794
4428.8
4395.9
4145.5
3064.5

income-statement-row.row.interest-income

402.19236122.9
16.1
11
10
7.7
4.2
0.8
1.7
2.8

income-statement-row.row.interest-expense

606.36261.741.518
21.6
228.9
105.5
2.4
1.2
0.2
2.5
7.1

income-statement-row.row.selling-and-marketing-expenses

63.85---
-
-
-
-
-
-
-
-

income-statement-row.row.total-other-income-expensenet

-596.47-170.2176.968.9
95
84.8
157.5
182.2
3
34.4
40.5
-34.8

income-statement-row.row.ebitda-ratio-caps

0---
-
-
-
-
-
-
-
-

income-statement-row.row.other-operating-expenses

96.71111.510.44.5
36.6
17.4
7.4
0.9
0.2
0.8
1798.9
0

income-statement-row.row.total-operating-expenses

-596.47-170.2176.968.9
95
84.8
157.5
182.2
3
34.4
40.5
-34.8

income-statement-row.row.interest-expense

606.36261.741.518
21.6
228.9
105.5
2.4
1.2
0.2
2.5
7.1

income-statement-row.row.depreciation-and-amortization

1638.341170.9647429.9
502.6
363.5
256.4
237.4
203.6
155.1
47.7
34.9

income-statement-row.row.ebitda-caps

6549.63---
-
-
-
-
-
-
-
-

income-statement-row.row.operating-income

4901.44216.642453876.1
3218.5
3088.8
2964.8
2455.6
1541.5
1059.7
942.7
866.1

income-statement-row.row.income-before-tax

4304.934046.444223945
3313.5
3173.6
3122.3
2637.7
1544.4
1094.2
983.3
831.4

income-statement-row.row.income-tax-expense

515.94304.8364.1393.6
348.4
262.1
172.5
218.7
195.9
201.6
277.9
247

income-statement-row.row.net-income

3864.393821.64061.13551.3
2965
2908
2941.1
2420.8
1335.7
892.3
704.2
582
类似股票
您可能还对以下内容感兴趣：
CHSYF
China Medical System Holdings Limited.
0.9313 USD
PNK
600479.SS
ZhuZhou QianJin Pharmaceutical Co.,Ltd.
10.92 CNY
SHH
WOCKPHARMA.BO
Wockhardt Limited.
532.5 INR
BSE
185750.KS
Chong Kun Dang Pharmaceutical Corp..
100300 KRW
KSC
300601.SZ
Shenzhen Kangtai Biological Products Co., Ltd..
22.39 CNY
SHZ
TKPHF
Takeda Pharmaceutical Company Limited.
26.83 USD
PNK
MVP.AX
Medical Developments International Limited.
0.61 AUD
ASX
APLLTD.NS
Alembic Pharmaceuticals Limited.
1001.35 INR
NSE
128940.KS
Hanmi Pharm. Co., Ltd..
321500 KRW
KSC
002390.KS
HANDOK Inc..
13700 KRW
KSC

常见问题

什么是 Eris Lifesciences Limited (ERIS.NS) 总资产是多少？

Eris Lifesciences Limited (ERIS.NS) 总资产为 36673280000.000.

什么是企业年收入？

年收入为 9840010000.000.

企业利润率是多少？

公司利润率为 0.818.

什么是公司自由现金流？

自由现金流为 19.153.

什么是企业净利润率？

净利润率为 0.210.

企业总收入是多少？

总收入为 0.266.

什么是 Eris Lifesciences Limited (ERIS.NS) 净利润？{{符号}}净利润（净收入）是多少？

净利润（净收入）为 3821580000.000.

公司总债务是多少？

债务总额为 8767110000.000.

营业费用是多少？

运营支出为 8898080000.000.

公司现金是多少？

企业现金为 -1906240000.000.